Physician Scientist, Adult Medicine-Trained Clinical Geneticist, and Cilium Enthusiast at the University of Pennsylvania. Moving to @tdrivas.bsky.social

Philadelphia, PA
Joined August 2020
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
MTSS1 may have a cardioprotective effect against diabetic cardiomyopathy in women, but not men, suggesting a biological basis for sex dimorphism in cardiac remodelling @PennCardiology @MGLevin @sday_hcm @damrauer @TDrivas ahajournals.org/doi/full/10.…
5
10
2,572
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
Today, RGC has published an important paper in @Nature today, describing an analysis of close to a million human exomes (n=983,578) as a single variant call set (!). This is the largest and most diverse rare variant database created so far. This impressive feat is accomplished by a large @RegeneronDNA team led by my wonderful colleague @suganthibala. @SunKat_y et al. Nature 2024 nature.com/articles/s41586-0… What kind of insights can we learn from sequencing ~980k exomes? Below is a summary of the major findings from the paper. ​ Background of RGC Regeneron Genetics Center (RGC) was established in 2014 just on time when major pharma companies started entering into the human genomics playfield. Last year, RGC celebrated its 10th year anniversary. I've written about the origin story of RGC before (xitter.cf/doctorveera/status/171…). ​ The business model of RGC is simple and efficient. It collaborates with academic institutions across the world and provide sequencing as free service in exchange for access to genotypic and phenotypic data. ​ The first successful collaboration was made with Geisinger Health system (GHS) to sequence 100,000 individuals, which was soon followed by an avalanche of large collaborations. Some of our largest collaborators include UK Biobank (N=500k), GHS (N=175k) and Mexico City Prospective Study (N=150k). Today, RGC has more than 300 collaborations around the world. Just a few months ago, it surpassed the milestone of 2 million exomes. What is described in the current paper is only a fraction of that sample. ​ Diversity of samples The 980k exome dataset come from a diverse set of samples. 23% (n=190k) of the participants are of non-European ancestries, the largest proportion to date for any similar datasets created so far. This includes both outbred populations and special populations enriched with communities with long-standing cultural history consanguineous and endogamous unions. ​ When it comes to human genetics, diversity is the key to making discoveries. Almost everyone agrees, and the field is embracing it now. But RGC is way ahead of the game. Just a few months ago, RGC partnered with other companies and laid the first foundational stone of what will become in a few years from now the world's largest genomics resource comprising half a million African Americans and Africans (xitter.cf/doctorveera/status/171…). ​ Variant survey Human genome is ~3 billion base pairs long. ~1% of which (~30 million base pairs), containing exons, is targeted by exome sequencing. By sequencing 980k exomes, the authors have captured ~16.5 million unique variants. That is, on average, one per every two base pairs across the exome. ​ The main goal of concentrating on exomes is to capture deleterious spelling errors in the genome, resulting in either loss or substantial decrease or, sometimes, increase in gene function. The authors have identified - ~1.1 million predicted loss of function variants (pLOFs), ~50% of which are singletons (that is, seen in just one individual) - ~10 million missense variants, 40% of which are singletons. ​ As expected, African ancestry groups had more variants (18% more) than any other ancestry group. ​ Footprints of selection pLOFs in the human genomes are like bullet holes in aircraft returning from war. The genes untouched or rarely hit by the pLOFs are the most critical genes, without which life is probably impossible. ​ Studying ~980k exomes, the authors have identified ~4000 genes that are depleted of pLOFs, suggesting they are indispensable. For more than 20% of these genes, we are learning their critical requirement for normal life for the first time. Previous datasets were not able to quantify their mutation constraints because of the shorter length. Most of these genes were not linked to a human disease yet. The current list will inspire many Mendelian discoveries in the near future. ​ Regional selection We have 10 times more missense variants than pLOFs, which means we can zoom into within genes and study which parts of a gene are indispensable and which parts aren't. ​ Not all parts of a protein are critical, but some parts are. For example, DNA binding regions of transcription factor protein, catalytic sites of an enzyme protein, transmembrane domains that forms the pore of channel proteins etc. With a knowledge of ~10 million missense variants from 980,000 humans, such critical regions are now starting to light up, illuminating the most crucial regions of proteins. For example, here is a trace of missense tolerance across different domains of cancer gene KRAS. Human genetics shows that the first 80 amino acids as the most critical region of KRAS, falling under the top 1 percentile of regional missense constrain metric. ​ Human knockouts The function of a gene in an organism is understood, typically, by studying the phenotypic consequences of deleting the gene. We cannot do such experiments in humans. But fortunately, Nature has already done this mutagenesis experiments for us. By studying naturally occurring human knockouts, we can assess the consequences of completely inhibiting a gene. This is crucial data for drug developers, as it informs about safety of drugs that act by inhibiting a gene or its product. ​ Studying the pLOFs across 980k humans, the authors have found 4.686 genes with at least one human knockout, suggesting that a life without these genes is likely possible. In line with that, the authors find that these genes are the ones that were mutationally least constrained (that is, they are enriched for pLOFs). For >1700 genes, we are learning for the first time humans completely lacking these genes do exist in this world. This is an incredible resource for drug development. Clinical genetics insights One of the most important use case of reference variant databases is to help clinical geneticists to identify disease causing variants in the patients. Historically, variant databases have been biased towards European populations. As a result, clinical geneticists struggle when they study exomes of non-European ancestry patients and often label the suspected variants as variants of unknown significance (VUS), because of a lack of proper reference database. ​ Cross-referencing the clinvar database with RGC dataset, the authors find European ancestry groups had more variants labelled "pathogenic" in Clinvar than African ancestry groups. Conversely, African ancestry groups had more VUS than European ancestry groups. This is not because Africans are protected from pathogenic variants, but simply reflect current databases are ignorant to clinically important variants in non-European ancestry individuals. With growing diverse databases such as the current one from RGC, the situation will soon change. ​ Conclusion RGC has created one of the largest reference database for studying human exomes. The implications of this resource are many, spanning all areas of human biology from basic science to drug discovery. ​ Congrats to all my colleagues (@SunKat_y et al.) on this incredible accomplishment. And thanks to all RGC collaborators and research participants without whom such a dataset wouldn't exist.
Something big happened a few days ago. Industry leaders in the genomics fields (Regeneron, AstraZeneca, Novo Nordisk and Roche) announced their collaboration with the US's largest black medical school, Meharry Medical College, Nashville, to establish what might become the UK Biobank of Africa--the largest genomics database of 500,000 volunteers from African ancestries (businesswire.com/news/home/2…) The lack of diversity in genomics databases is today's greatest barrier to scientific progress. To break down this barrier, we need scientific minds, money, power and importantly, trust and engagement from the underrepresented communities. That can happen only when academia, industry and underrepresented communities join hands together to change the future. Just a week ago, the Regeneron Genetics Center (RGC), AstraZeneca and AbbVie published the largest genomics database of Mexican-Americans (N=150,000) in collaboration with academic institutes in Oxford and Mexico (nature.com/articles/s41586-0…) (I'll write a separate post on this). Now, RGC and other industry partners have established the Diaspora Human Genomics Institute (DHCI). Check out this website (thedhgi.org/) and the launch event. Note, this is not just a commitment towards establishing a genomics database. The initiative will also ensure to uplift the African communities by funding the education and training of young African and African-American students and researchers in the genomics field. One of those things about RGC that inspire me most is their commitment to improving diversity in the genomics databases. One of the many reasons why RGC is being flooded with top scientists from all over the world.
11
209
12
700
124,843
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
One of my graduate students dropped by my office, exasperated, and said, "I don't know how to innovate. So, how can I do a PhD?". I erased my whiteboard and began listing strategies for generating new research ideas. They left reassured and excited! As #professors, we mentor and make knowledge accessible to empower our students. I hope this is helpful to others! #academicchatter #Phdlife #Highered
26
624
29
2,879
335,565
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
Do bakers daydream about leaving their job to do a PhD in molecular biology?
54
826
95
7,855
569,133
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
Heading back after a fantastic week at @AMIAinformatics. It was also first conference presentation from my lab. @5inghalp gave an amazing talk on how we're leveraging LLMs to intuitively structure clinical notes for phenotyping tasks. #IS24
1
2
18
1,116
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
#LGBTQ happy hour at @TheACMG 🌈 🧬 #prideinmedicine #gaydoctor #queer @TDrivas
2
17
5,588
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
We love our community! Please join us for a day of self-care, self-love, and wellness during the week of Valentine’s Day! We will be providing wellness baskets and a wellness workshop on February 15th. Registration: forms.gle/yQ64unACgYdPtCWp7
5
8
842
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
Celebrating Dr. @MaraCowen who defended her amazing thesis work yesterday! I owe so much to Brandon and Mara for all of their work and ideas, and can’t thank them enough!! What a week!! – at Philadelphia, PA
7
2
50
4,901
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
So proud of Dr. Brandon Bastien (@PennNGG)! The first PhD from my lab - and who gave a terrific summary of his thesis work yesterday!! Congrats Brandon!!
3
5
1
74
7,998
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
In the constant quest to understand disease, @PennMedicine has a huge advantage: the Penn Medicine BioBank, a huge repository of DNA from a diverse population. Check out the @TomAvril1 story inquirer.com/health/penn-med…
3
5
1
12
2,456
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
(1/3) Often, when asked what I do for a living, Im met with a perplexed look by folks outside of (& sometimes even within) the field of medicine. Heck, even my own Mother doesnt have a good grasp on what it is I do. This lead me to look at some data on types of patients I’ve seen
1
3
20
1,232
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
🌈 Hey #ASHG23 attendees β€” let’s coordinate an #LGBTQ (and allies!) meet up! A safe space to connect, share, and uplift. Tomorrow, Friday 11/3 at 9PM at The Little Gay Pub (1100 P St NW). Spread the word, tag, and retweet, please! πŸ“£#InclusionInAcademia #PrideInScience #Genetics
2
7
13
2,468
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
Alexander Smith @Brokaryote from the Zackular lab @joeyzacks defends tomorrow!!
3
1
21
5,442
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
Mark your calendars for the first LTBGS meeting of the year! We hope to see you all there!
9
1
18
2,388
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
New paper on the "Phenotypes of undiagnosed adults with actionable OTC and GLA variants," which examined the medical history of patients in the MGB and Penn biobanks with variants associated with OTC deficiency and Fabry disease, is out now. Read here: bit.ly/3DY2dW9
πŸ’«New @HGGAdvances πŸ“°Phenotypes of undiagnosed adults with actionable OTC and GLA variants πŸ§‘β€πŸ€β€πŸ§‘@nbgmd @RegeneronDNA & colleagues πŸ‘‰rb.gy/uh3ou
1
5
11
4,617
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
Lab hangout for #GardenJams and some history!! Joined by our awesome summer undergrad interns (SUIP @IDEAL_Research and PGSIP @PennGenetics), @TDrivas lab, and ran into @EBhoj lab!! Check out this fun event Wednesdays in July @pennmuseum!!
3
15
1,841
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
She is majestic. She is captivating. She is the moment. She is learning all about the latest genomics research by using our talking glossary of terms. genome.gov/genetics-glossary
3
24
3
117
29,019
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
A MUST read for anyone and everyone in #STEM fields. "Juneteenth not only commemorates the past. It calls us to action today... Juneteenth should also be a day of reflection on how science has a racism problem as well as the potential mechanisms to fix it."
As part of the current @CellCellPress issue 52 Black science faculty came together to comment on Juneteenth in STEMM, the barriers to equitable science, and institutional-level solutions. Thank you @phdgprotein86 for your vision and leadership. cell.com/cell/fulltext/S0092…
1
10
1,203
Theodore G. Drivas πŸ³οΈβ€πŸŒˆ retweeted
BWF Announces 2023 Career Awards For Medical Scientists buff.ly/45OMLIF #bwfcams
13
21
53
63,424